Trial Profile
Treatment of Portal, Mesenteric, and Splenic Vein Thrombosis With Rivaroxaban. A Pilot, Prospective Cohort Study
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 30 Jan 2022
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Thrombosis; Venous thromboembolism; Venous thrombosis
- Focus Adverse reactions
- Acronyms RIDTS; RIVASVT-100
- 14 Dec 2021 Results (N=100) of the 3-month follow-up presented at the 63rd American Society of Hematology Annual Meeting and Exposition
- 01 May 2017 Planned End Date changed from 1 Dec 2018 to 1 Dec 2019.
- 01 May 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Jun 2019.